Senti Biosciences Holdings, Inc. (SNTI) stock
SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.04 (-28.68%)
Close on Nov 17, 2026Market cap $3.02MP/E –Yield –
Senti Biosciences cash
Cash and short-term investments held at the end of each period.
Senti Biosciences's cash was $6.46M at Jun 30, 2026. For fiscal 2025 it was $16.42M, down 68.3% from the year before. The highest annual figure on record is $98.60M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.42M | -68.3% |
| FY2024 | Dec 31, 2024 | $51.82M | +44.3% |
| FY2023 | Dec 31, 2023 | $35.90M | -63.6% |
| FY2022 | Dec 31, 2022 | $98.60M | +76.1% |
| FY2021 | Dec 31, 2021 | $56.00M | +80.4% |
| FY2020 | Dec 31, 2020 | $31.03M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.46M | -74.3% |
| Q1 FY2026 | Mar 31, 2026 | $8.94M | -76.1% |
| Q4 FY2025 | Dec 31, 2025 | $16.42M | -68.3% |
| Q3 FY2025 | Sep 30, 2025 | $12.24M | -12.8% |
| Q2 FY2025 | Jun 30, 2025 | $25.11M | +29.4% |
| Q1 FY2025 | Mar 31, 2025 | $37.35M | +34.6% |
| Q4 FY2024 | Dec 31, 2024 | $51.82M | +44.3% |
| Q3 FY2024 | Sep 30, 2024 | $14.04M | -64.4% |
| Q2 FY2024 | Jun 30, 2024 | $19.41M | -67.4% |
| Q1 FY2024 | Mar 31, 2024 | $27.75M | -63.5% |
| Q4 FY2023 | Dec 31, 2023 | $35.90M | -63.6% |
| Q3 FY2023 | Sep 30, 2023 | $39.40M | -65.7% |
| Q2 FY2023 | Jun 30, 2023 | $59.60M | -57.4% |
| Q1 FY2023 | Mar 31, 2023 | $76.10M | +99.5% |
| Q4 FY2022 | Dec 31, 2022 | $98.60M | +76.1% |
| Q3 FY2022 | Sep 30, 2022 | $114.94M | +56.0% |
| Q2 FY2022 | Jun 30, 2022 | $139.80M | +68.6% |
| Q1 FY2022 | Mar 31, 2022 | $38.14M | – |
| Q4 FY2021 | Dec 31, 2021 | $56.00M | +80.4% |
| Q3 FY2021 | Sep 30, 2021 | $73.69M | – |
| Q2 FY2021 | Jun 30, 2021 | $82.94M | – |
| Q1 FY2021 | Mar 31, 2021 | $0 | – |
| Q4 FY2020 | Dec 31, 2020 | $31.03M | – |
See a number that looks wrong?